Trials / Completed
CompletedNCT00335452
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25,086 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clopidogrel | oral administration |
| DRUG | acetylsalicyclic acid (ASA) | oral administration |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2006-06-09
- Last updated
- 2010-11-18
- Results posted
- 2010-10-07
Locations
38 sites across 38 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00335452. Inclusion in this directory is not an endorsement.